• Publications
  • Influence
Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.
CONTEXT Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternativeExpand
  • 2,868
  • 58
Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
BACKGROUND The prevalence of patent foramen ovale among patients with cryptogenic stroke is higher than that in the general population. Closure with a percutaneous device is often recommended in suchExpand
  • 763
  • 43
  • PDF
Guidelines for the Early Management of Patients With Ischemic Stroke: A Scientific Statement From the Stroke Council of the American Stroke Association
In 1994, a panel appointed by the Stroke Council of the American Heart Association authored guidelines for the management of patients with acute ischemic stroke.1 After the approval of the use ofExpand
  • 1,211
  • 29
  • PDF
Trial Design and Reporting Standards for Intra-Arterial Cerebral Thrombolysis for Acute Ischemic Stroke
Background and Purpose— The National Institutes of Health (NIH) estimates that stroke costs now exceed $45 billion per year. Stroke is the third leading cause of death and one of the leading causesExpand
  • 977
  • 18
Use of tissue-type plasminogen activator for acute ischemic stroke: the Cleveland area experience.
CONTEXT Little is known regarding outcomes after intravenous tissue-type plasminogen activator (IV tPA) therapy for acute ischemic stroke outside a trial setting. OBJECTIVE To assess the rate of IVExpand
  • 676
  • 17
  • PDF
The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase
Background and Purpose— Most acute ischemic stroke patients arrive after the 3-hour time window for recombinant tissue plasminogen activator (rtPA) administration. The Desmoteplase In Acute IschemicExpand
  • 1,010
  • 16
  • PDF
Guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association.
In 1991, about 500 000 Americans had a stroke (400 000 had an ischemic stroke) and more than 143 000 died. More than 3 000 000 people in the .Ignited States have survived a stroke. In 1994 the annualExpand
  • 498
  • 14
  • PDF
The Warfarin-Aspirin Symptomatic Intracranial Disease Study
We conducted a retrospective, multicenter study to compare the efficacy of warfarin with aspirin for the prevention of major vascular events (ischemic stroke, myocardial infarction, or sudden death)Expand
  • 514
  • 13
Pharmacological management of chronic neuropathic pain: Revised consensus statement from the Canadian Pain Society
Neuropathic pain is defined as a lesion or disease of the somatosensory system, and may involve the central or peripheral nervous systems. Treatment of neuropathic pain is a challenge for cliniciansExpand
  • 282
  • 13
  • PDF
Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset
Background and Purpose— Desmoteplase is a novel plasminogen activator with favorable features in vitro compared with available agents. This study evaluated safety and efficacy of intravenous (IV)Expand
  • 553
  • 11
  • PDF